Cardiogen

Overview

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg / AEDR) from the Khavinson bioregulator series, studied in Russian preclinical models for potential effects on cardiac-tissue gene expression and cardiomyocyte structural proteins. Not FDA-approved; no Western clinical trials have been performed, and all published evidence originates from a single research group.

Mechanism of Action

Proposed mechanism per the Khavinson model: the tetrapeptide penetrates cells, enters the nucleus, and modulates expression of cytoskeletal and nuclear-matrix proteins (actin, tubulin, vimentin, lamin A/C) in cardiomyocytes and fibroblasts. Receptor-level mechanism and downstream cardioprotective pathways remain hypothetical.

Research Summary

Evidence is limited to preclinical work from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson et al. (Bull Exp Biol Med, 2012; PMID 22977870) reported that H-Ala-Glu-Asp-Arg-OH increased expression of cytoskeletal and nuclear-matrix proteins in cultured mouse embryonic fibroblasts. There are no independently replicated studies, no randomized controlled trials, and no peer-reviewed evidence of clinical cardioprotective efficacy in humans.

Vendors selling Cardiogen

Scored vendors carrying Cardiogen, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Limited human safety data
• Mild injection site reactions (preclinical)
• No significant adverse effects in published preclinical studies
• Theoretical risk of fibroblast overstimulation at high doses

Compare Cardiogen with Others

Research References

• Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins (2012)

Frequently asked questions

Has Cardiogen been independently lab-tested?

Disclosed Labs has collected 11 Certificates of Analysis (COA) for Cardiogen from 6 independent testing labs. 8 vendors have submitted material for testing. Products average 99.6% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/cardiogen/testing.

What is the average purity of Cardiogen on the market?

Based on 11 COAs analyzed by Disclosed Labs, Cardiogen products average 99.6% (±0.4%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/cardiogen/coas.

Where can researchers source Cardiogen?

6 vendors with Disclosed Labs trust grades currently list Cardiogen, including Peptidology, Peptide Supply Co., Verified Peptides. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/cardiogen.

How does Cardiogen work?

Proposed mechanism per the Khavinson model: the tetrapeptide penetrates cells, enters the nucleus, and modulates expression of cytoskeletal and nuclear-matrix proteins (actin, tubulin, vimentin, lamin A/C) in cardiomyocytes and fibroblasts. Receptor-level mechanism and downstream cardioprotective pathways remain hypothetical.

What does the research say about Cardiogen?

Evidence is limited to preclinical work from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson et al. (Bull Exp Biol Med, 2012; PMID 22977870) reported that H-Ala-Glu-Asp-Arg-OH increased expression of cytoskeletal and nuclear-matrix proteins in cultured mouse embryonic fibroblasts. There are no independently replicated studies, no randomized controlled trials, and no peer-reviewed evidence of clinical cardioprotective efficacy in humans.